In May, MYOS CORP announced the launch of MYOS MD, an advanced nutrition product line created to help reduce muscle loss associated with aging, disuse and medical treatment.
MYOS MD products are powered by the proprietary ingredient Fortetropin®, an all-natural bioactive compound shown in clinical studies to increase muscle growth, enhance rate of muscle protein synthesis and lower levels of circulating myostatin, noted a MYOS CORP press release.
Potential use cases for MYOS MD include:
- Limiting general muscle loss associated with aging
- Limiting muscle loss from use of obesity medications
- Ensuring effective muscle recovery pre/post-orthopedic surgery
“For several years we’ve felt very strongly about the potential for Fortetropin to play a big role in the medical nutrition space, and we’re very excited to launch MYOS MD at this time,” said MYOS CORP CEO Joe Mannello.
“Our product is backed by strong clinical science and meets a significant need in the marketplace. The doctors we’ve spoken to say they are in desperate need of a safe, effective, all-natural product that can assist in reducing muscle loss in their patients. We’ve gotten tremendous early reception from the medical world, and we’re extremely excited about the growth potential of this business.”
Age-related muscle loss is the gradual loss of muscle mass and function that occurs with aging. This condition affects millions of adults over the age of 50 and worsens as age increases, leading to decreased strength, mobility issues and a higher risk of falls and fractures, significantly impacting an individual’s independence and quality of life. This type of muscle loss is caused by several factors, including reduced physical activity, changes in hormone levels and decreased protein synthesis.
William Evans, PhD, a distinguished scholar at both the University of California-Berkley and Duke University, is an internationally recognized expert in muscle science research. His group’s 2020 publication illuminated the potential of Fortetropin, a major ingredient in MYOS MD, demonstrating how this singular proteo-lipid compound resulted in a substantial 18% elevation in the rate muscle protein synthesis in older adults. Notably, this enhancement occurred without any increase in physical activity on the part of the subjects, suggesting that Fortetropin has inherent anabolic properties, even for inactive individuals.
“Fortetropin has a robust effect on the rate of muscle protein synthesis in older men and women. It is rare for a nutrition product to show such a consistent and positive effect,” Evans said of the results in 2020.
MYOS MD’s potential uses with weight-loss products
The results of the 2020 study provide implications for the challenge of preserving muscle mass during treatment with new weight loss products, as the adoption of such drugs has skyrocketed across the U.S. Use of products containing GLP-1 agonists (such as semaglutide) result in weight loss resulting from reduced appetite and decreased food intake. However, as with many weight loss products, use of GLP-1 products can lead to muscle loss.
Although there is currently no direct evidence linking Fortetropin’s efficacy in counteracting muscle loss to weight loss products, experts such as Evans consider it a compelling avenue warranting deeper exploration. By combining a muscle health product like Fortetropin with a weight loss product, users should enjoy weight loss benefits without the same degree of muscle depletion.
“Stimulation of muscle protein synthesis, which Fortetropin has shown it provides, can have a positive effect of preserving muscle mass and increasing fat loss,” said Evans. “The loss of muscle mass is common when individuals, especially as we age, lose weight rapidly.”
Embracing this potential, MYOS envisions a synergistic approach, contemplating the pairing of Fortetropin with weight loss treatments. This could create an optimal balance, allowing individuals to reduce excess weight without compromising precious lean muscle mass.
“Fortetropin’s distinct advantage is its power to boost muscle growth and reduce muscle loss, all in a low-calorie offering. It’s an ideal choice for those aiming to shed weight without compromising muscle integrity,” Mannello said. “Metabolism is your body’s mechanism of transforming intake into energy. A robust muscle mass increases your metabolic rate. However, when weight and muscle decrease, your metabolism decelerates, hindering your weight loss progress.”
Additional notable research results
In addition to the aforementioned study at Cal Berkeley, several other studies of Fortetropin have shown its positive effect on muscle health. Clinical trials have shown that supplementation with Fortetropin:
- Lowered circulating myostatin in young males, favoring a positive net muscle protein balance supporting muscle growth or attenuating muscle loss.
- Prevented a rise in circulating myostatin in young men undergoing leg immobilization to create muscle disuse; this may be important in mitigating disuse-induced atrophy and aiding recovery.
- Prevented a rise in serum myostatin and limited loss of muscle mass in a study with 100 dogs after tibial plateau leveling osteotomy (TPLO) surgery, a procedure done when the cranial cruciate ligament has ruptured.
For more information on MYOS MD, please contact Greg Arabatzis at [email protected].
About MYOS CORP
MYOS CORP is a Cedar Knolls, New Jersey-based medical nutrition company that develops products that improve muscle health in people and animals. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size and lean body mass and reduce muscle atrophy. For more information, please visit myoscorp.com.